Goldman Sachs China Healthcare Corporate Day summary: Focus on the re-entry window after derisking

Overview

This is a Goldman Sachs “On the Road with Goldman Sachs – Asia Pacific” podcast-style research document covering China Healthcare Corporate Day. Hosted by Michael Snaith, the report invites Asia Healthcare Analyst Chris Pan and China Healthcare Analyst Linhai Zhao to discuss observations from recent Corporate Day activities. The material is closer to a conference summary and research gateway than a complete in-depth company report.

Core views

The key takeaway is that Goldman Sachs has recently conducted company research and investor engagement around the China Healthcare sector, summarizing the related research theme as “the derisked window for re-entry opens.” However, the current text does not elaborate on specific drivers, company names, earnings forecasts, or valuation derivations. Therefore, the sector view can only be interpreted as cautiously constructive rather than an explicit broad bullish conclusion.

Analysis framework

The report uses a podcast interview and conference-summary format, with analysts covering Asian and Chinese Healthcare sharing roadshow observations, company discussions, and investor feedback. The appendix also describes research tools commonly used by Goldman Sachs, including the GS Factor Profile, M&A Rank, and Quantum database. In this document, however, these methods primarily serve as disclosure and methodological background and do not produce quantitative conclusions for individual companies.

Methodology notes

• Equity Factor ProfileGS Factor Profile

  Evaluates stock characteristics through growth, financial returns, valuation multiples, and composite percentiles.

  Goldman Sachs standardizes forward sales growth, EBITDA growth, EPS growth, ROE, ROCE, CROCI, and metrics such as P/E, P/B, and EV/EBITDA, converting them into percentiles to compare individual stocks with the broader market and industry peers.

• M&A Scenario AssessmentM&A Rank

  Scores covered companies according to their probability of becoming acquisition targets.

  Goldman Sachs assigns companies a probability of becoming M&A targets on a scale from 1 to 3: 1 represents a higher probability, 2 represents a medium probability, and 3 represents a lower probability. For companies ranked 1 or 2, an M&A component may be incorporated into the target price.

• Financial DatabaseQuantum

  Goldman Sachs’ proprietary database of financial histories, forecasts, and ratios.

  Quantum can be used for in-depth analysis of individual companies as well as comparisons across companies, industries, and markets, but this report does not present any specific Quantum outputs.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Healthcare equities

  Core research subject

  Strengths

  The sector has undergone a certain degree of derisking, and the related Goldman Sachs research title suggests that a re-entry window may be opening.

  Weaknesses

  The report does not provide specific company earnings forecasts, valuation multiples, or financial data, making it difficult to screen individual stocks directly.

  Comparison

  Compared with an in-depth company report, this material is more focused on a podcast summary and conference guidance, with lower information density.

  Risks

  Policy changes, drug pricing pressure, clinical and approval uncertainties, and fluctuations in investor risk appetite.

Key data

• Number of stocks covered globally by Goldman Sachs3,074As of 2026-04-01, Goldman Sachs Global Investment Research provided investment ratings for 3,074 stocks.
• Global rating distributionBuy 50%; Hold 34%; Sell 16%From the Rating Distribution table in the disclosure appendix.
• Distribution of investment banking relationshipsBuy 65%; Hold 60%; Sell 45%The disclosure table shows the proportion of companies in each rating category that had an investment banking relationship with Goldman Sachs during the past twelve months.
• Primary speaking analystsChris Pan; Linhai ZhaoChris Pan is the Asia Healthcare Analyst, and Linhai Zhao is the China Healthcare Analyst.

Impact & implications

The main implication for investors is that the China Healthcare sector may have entered a reassessment phase. Following the release of earlier risks, investors may need to refocus on company fundamentals, investor feedback, and policy or industry catalysts. However, the current text does not provide a clear buy list or valuation framework, so actual investment decisions still require the relevant complete research reports and company-level data.

Risks

• The main report lacks specific company names, financial forecasts, ratings, and target prices, limiting the actionable value of its investment conclusions.
• Podcasts and conference summaries generally reflect research feedback at a particular stage and may not replace complete models and in-depth company research.
• The Healthcare sector may remain exposed to regulatory policies, medical insurance cost controls, R&D failures, and changes in the financing environment.
• The disclosures indicate that Goldman Sachs and its affiliates may have investment banking or trading relationships with covered companies.

What to watch

• Specific company views in the subsequent full report, “China Healthcare: Mid-year Corporate Day Takeaway: The derisked window for re-entry opens.”
• Earnings guidance, order/prescription trends, R&D pipeline progress, and marginal policy changes at Chinese Healthcare companies.
• Capital inflows into the China Healthcare sector and the sustainability of valuation recovery.
• Whether Goldman Sachs raises individual stock ratings, target prices, or earnings forecasts in subsequent reports.